Found 813 Enz. Inhib. hit(s) with Target = 'Proto-oncogene tyrosine-protein kinase receptor Ret [V804L]'
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair